Pasithea Therapeutics Corp. Share Price & Technical Analysis
KTTA · $0.68 (-2.86%)
Healthcare / Biotechnology
$0.68
-2.86%
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); …
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -19% avg return in past 3 year May month.
-53% return in 2026, -28% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -31% | 0% | -22% | 0% | 0% | – | – | – | – | – | – | – | -53% |
| 25 | -31% | -45% | 18% | 31% | -37% | -30% | 0% | 14% | -12% | 14% | 88% | 0% | 8% |
| 24 | -11% | 23% | -9% | -4% | -20% | -9% | 0% | -10% | 17% | -30% | -18% | 3% | -67% |
| 23 | 8% | -31% | -24% | -5% | 1% | 32% | 28% | -1% | -21% | -22% | -7% | 16% | -26% |
| 22 | -26% | -18% | 29% | -8% | -27% | 18% | 16% | 2% | 6% | -16% | -8% | -34% | -67% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$19.68M
P/E ratio
—
52W high
$2.06
52W low
$0.28
Volume
1,57,878
Beta
0.22
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Pasithea Therapeutics Corp. share price today?
- Pasithea Therapeutics Corp. (KTTA) last traded around $0.68 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KTTA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KTTA. Download the app for real-time alerts.
- How can I analyze Pasithea Therapeutics Corp. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.